(MENAFN- ProactiveInvestors)
Limited () and The University of Queensland’s Institute for Molecular Bioscience have been granted a 3 year $670000 linkage grant from the Australian Research Council (ARC).
This is one of largest grants awarded by the ARC this year and will be used to assist in the development of a novel platform to generate macrocyclic Phylomer libraries.
Macrocycles are an emerging class of therapeutic peptides that have been chemically modified to form circular structures.
‘Cyclised’ peptides have very favourable drug-like properties which allow them to bind more effectively to drug targets and to resist being broken down in the body like normal peptides.
In some cases macrocyclics can be chemically engineered to enter cells and hit targets inaccessible to conventional drugs.
This capability would further add to ’s ability to deliver drugs inside cells.
’s technology allows for much greater versatility in the choice of amino acids that can be joined in the cyclisation step.
This flexibility significantly expands the structural and size diversity of the Phylomer libraries allowing them to access a broader landscape of druggable targets.
It also has potential to improve the scale and efficiency of downstream processing thereby overcoming a major bottleneck of alternative macrocyclisation platforms.
Proactive Investors Australia is the market leader in producing news articles and research reports on ASX emerging companies with distribution in Australia UK North America and Hong Kong / China.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.